Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM. It demonstrates significant enhancement of hepatocyte glucose uptake (38%). This compound holds great potential for studying various diseases including diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 10-14周 | ||
50 mg | ¥ 13,800 | 10-14周 | ||
100 mg | ¥ 17,500 | 10-14周 |
产品描述 | GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM. It demonstrates significant enhancement of hepatocyte glucose uptake (38%). This compound holds great potential for studying various diseases including diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1]. |
体外活性 | GSK-3β inhibitor 6 (Compound B30, 0-30 μΜ, 30 min) shows good GSK-3β kinase inhibitory activity (IC 50 : 24.4 μM) [1]. GSK-3β inhibitor 6 (5 μM, 3 h) shows high hepatocyte glucose uptake (38%) with no significant toxicity against HepG2 cells [1]. |
体内活性 | GSK-3β inhibitor 6 (Compound 5k, oral administration, 20 mg/kg) shows favorable drug-like properties (t 1/2 : 1.41 h, C max : 288 ng/mL) [2]. Animal Model: Sprague-Dawley rats (pharmacokinetic assay) [2] Dosage: 2 mg/kg, 20 mg/kg Administration: Intravenous injection (2 mg/kg), oral administration (20 mg/kg) Result: Pharmacokinetic profile of GSK-3β inhibitor 6 (Compound 5k). Compound Route Dose (mg/kg) t 1/2 (h) Tmax (h) C max (ng/mL) AUC 0-t (hr ng/mL) AUC 0-∞ (hr ng/mL) CL (mL/hr/kg) F (%) GSK-3β inhibitor 6 Oral administration 20 1.41 1.33 288 1030 1073 18719 11.4 GSK-3β inhibitor 6 Intravenous injection 2 2.13 0.08 449 872.89 940.48 2190.83 F: oral bioavailability. |
分子量 | 393.28 |
分子式 | C20H17BrN4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK-3β inhibitor 6 Inhibitor inhibitor inhibit